OpportunityTitle: Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator
AdditionalInformationOnEligibility: Research institutions and Non-domestic (non-U.S.) entities are eligible.  Application Screening Criteria Applications that fail to meet the screening criteria described below will not be reviewed and will receive no further consideration.                                                                   1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM EDT  2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM EST outlining the project abstract and approximate funding request. Letters of intent should be sent by email to the attention of Dr. Joseph Larsen at joseph.larsen@hhs.gov. Please see Attachment F: Letter of Intent  for additional instructions and a template.  3. A pre-application workshop will be held on March 3, 2016 from 3:00PM to 5:00PM EST in the Hubert H. Humphrey Building, in the Auditorium, located at 200 Independence Ave SW, Washington, DC 20201 RSVP to this meeting by emailing, Dr. Joseph Larsen at joseph.larsen@hhs.gov, Subject Line: RSVP for Accelerator Pre-Application Workshop by February 29, 2016 at 5:00 PM EST. Please include Names, Titles, Organizations, Email, Phone and country of citizenship for each member on your team that will attend.  4. A Technical Assistance Conference Call will be held for only parties that have submitted Letters of Intent  on March 18, 2016 at 11:00AM EST. This meeting is designed to address any questions associated with an application process. BARDA will address any clarifying questions submitted with the Letter of intent A conference call number will be provided prior to the meeting to only parties that have submitted  letters of Intent
Description: The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&amp;D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&amp;D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&amp;D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.
GrantorContactEmailDescription: Grants.gov Customer Support
GrantorContactText: Grants.gov Contact Center&lt;br/&gt;Phone Number: 1-800-518-4726&lt;br/&gt;&lt;br/&gt;Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays.&lt;br/&gt;support@grants.gov&lt;br/&gt;
CloseDateExplanation: Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT.  ASPR will not accept any applications that are not submitted electronically via www.grants.gov.